AARD vs RARE · $284.4M cap vs rev $350.0M
Aardvark Therapeutics, Inc. Common Stock (AARD) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Aardvark Therapeutics, Inc. Common Stock (AARD) is a biotechnology company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported AARD revenue for 2025-12-31 was $0. Net income was -$57.6M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AARD currently screens at market cap $284.4M.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
AARD currently screens at market cap $284.4M. RARE currently screens at market cap $2.79B.
Not investment advice. Open the AARD and RARE stock pages for the full models.
Not investment advice.